Corona Remedies IPO Subscription Status
Corona Remedies IPO closed on 10 December 2025 with an overall subscription of 144.49x based on shares applied. QIB demand came in at 293.80x, NII at 220.18x, and retail at 30.29x.
Allotment will be finalised on 11 December 2025. The stock is scheduled to list on NSE and BSE on 15 December 2025.
Issue Price
Rs 1,062.00
GMP Today
Rs 342.00 (+32.20%)
Overall Subscription
144.49x
Issue Size
₹655.37 Cr
Allotment Date
11 Dec 2025
Listing Date
15 Dec 2025
Corona Remedies IPO Subscription by Amount
Category-wise subscription based on amount applied at issue price Rs 1,062.00
| Category | Amount Offered | Amount Applied | Subscription |
|---|---|---|---|
| QIB | Rs 129.75 Cr | Rs 38,119.37 Cr | 293.80x |
| FII | - | Rs 9,265.99 Cr | - |
| DFI | - | Rs 16,543.28 Cr | - |
| Mutual Funds | - | Rs 2,339.56 Cr | - |
| Other | - | Rs 9,970.54 Cr | - |
| NII | Rs 97.38 Cr | Rs 21,441.47 Cr | 220.18x |
| bNII (above Rs 10L) | Rs 64.92 Cr | Rs 16,014.25 Cr | 246.67x |
| Corporate | - | Rs 134.10 Cr | - |
| Individual | - | Rs 14,988.40 Cr | - |
| Other | - | Rs 891.75 Cr | - |
| sNII (Rs 2L to Rs 10L) | Rs 32.46 Cr | Rs 5,427.21 Cr | 167.20x |
| Corporate | - | Rs 10.02 Cr | - |
| Individual | - | Rs 5,171.45 Cr | - |
| Other | - | Rs 245.74 Cr | - |
| Retail | Rs 227.22 Cr | Rs 6,881.97 Cr | 30.29x |
| Cut-off price | - | Rs 5,709.31 Cr | - |
| Fixed price | - | Rs 1,172.66 Cr | - |
| Employee | Rs 6.16 Cr | Rs 95.89 Cr | 15.56x |
| Cut-off price | - | Rs 76.12 Cr | - |
| Fixed price | - | Rs 19.77 Cr | - |
| Total | Rs 460.51 Cr | Rs 66,538.70 Cr | 144.49x |
Corona Remedies IPO Subscription by Applications
Category-wise subscription based on applications received
| Category | Applications Offered | Applications Received | Subscription |
|---|---|---|---|
| QIB | 12,21,729 | 6,584 | 0.01x |
| FII | - | 144 | - |
| DFI | - | 97 | - |
| Mutual Funds | - | 31 | - |
| Other | - | 6,312 | - |
| NII | 4,678 | 4,05,165 | 86.61x |
| bNII (above Rs 10L) | 3,119 | 1,55,201 | 49.76x |
| Corporate | - | 1,097 | - |
| Individual | - | 1,45,362 | - |
| Other | - | 8,742 | - |
| sNII (Rs 2L to Rs 10L) | 1,559 | 2,49,964 | 160.34x |
| Corporate | - | 412 | - |
| Individual | - | 2,37,973 | - |
| Other | - | 11,579 | - |
| Retail | 1,52,827 | 37,91,888 | 24.81x |
| Cut-off price | - | 31,15,556 | - |
| Fixed price | - | 6,76,332 | - |
| Employee | 4,145 | 35,562 | 8.58x |
| Cut-off price | - | 29,450 | - |
| Fixed price | - | 6,112 | - |
| Total | 13,83,379 | 42,39,199 | 3.06x |
What Do These Subscription Numbers Mean?
A subscription of 144.49x by shares means the IPO received bids for 144 times the shares reserved. Allotment odds depend on application count in each category, not share volume.
Here is what each category number tells you:
QIB at 293.80x by shares: This is the strongest signal on the page. QIBs are institutional investors, mutual funds, foreign institutions, and banks. When they subscribe at 293.80x, it reflects serious institutional conviction.
NII at 86.61x by applications: NII includes high net worth individuals applying above Rs 2 lakh. Proportional allotment uses application subscription. bNII came in at 49.76x and sNII at 160.34x by applications. Share subscription was 220.18x. Allotment uses application count, not share volume.
At 24.81x subscription by applications, approximately 1 in 25 retail applicants can expect an allotment (~4% per application). Retail allotment is done by lottery when oversubscribed. Share subscription was 30.29x. Allotment uses application count, not share volume.
At 8.58x subscription by applications, approximately 1 in 9 employee applicants can expect an allotment (~12% per application). Employee reservation uses the same lottery logic as retail when oversubscribed.
Corona Remedies IPO Allotment Chances
Allotment odds below use application subscription (number of bids received), not share or amount subscribed.
Retail
- •Application subscription: 24.81x.
- •Allotment odds: about 1 in 25 (~4% chance per application).
- •Method: Lottery. If allotted, you receive at least one lot.
- •Share subscription was 30.29x. Allotment uses application count, not share volume.
- •One application per PAN. Multiple eligible accounts in a household can improve overall family odds, not individual odds.
SHNI (Rs 2 lakh to Rs 10 lakh)
- •Application subscription: 160.34x.
- •Allotment odds: about 1 in 160 for a minimum-lot application (~1% of the applied lot on average).
- •Method: Proportional. Shares allotted are based on your bid size, not a lottery.
- •Share subscription was 167.20x. Allotment uses application count, not share volume.
BHNI (above Rs 10 lakh)
- •Application subscription: 49.76x.
- •Allotment odds: about 1 in 50 for a minimum-lot application (~2% of the applied lot on average).
- •Method: Proportional. Shares allotted are based on your bid size, not a lottery.
- •Share subscription was 246.67x. Allotment uses application count, not share volume.
Check the Corona Remedies IPO Allotment Status page from 11 December 2025 for your allotment result.
Corona Remedies IPO GMP After Subscription
GMP for Corona Remedies IPO stands at Rs 342.00 today, giving an estimated listing price of Rs 1,404.00 per share.
A subscription of 144.49x combined with a GMP of 32.20% is a strong combination heading into listing. QIB demand above 50x in particular tends to support listing sentiment, as institutional investors are seen as informed buyers.
Track live GMP on the Corona Remedies IPO GMP Today page or the IPOwiz Live IPO GMP Tracker.
Corona Remedies IPO Day-wise Subscription
| Day | QIB | NII | Retail | Overall |
|---|---|---|---|---|
| Day 1 - 8 Dec 2025 | 0.00x | 0.84x | 0.96x | 0.67x |
| Day 2 - 9 Dec 2025 | 1.76x | 28.37x | 6.90x | 9.96x |
| Day 3 - 10 Dec 2025 | 293.80x | 220.18x | 30.39x | 144.54x |
Corona Remedies IPO Key Dates
| Event | Date |
|---|---|
| IPO Open Date | 8 December 2025 |
| IPO Close Date | 10 December 2025 |
| Allotment Date | 11 December 2025 |
| Refund Initiation | 12 December 2025 |
| Share Credit to Demat | 12 December 2025 |
| Listing Date | 15 December 2025 |
| Minimum Investment | Rs 14,868.00 |
| Lot Size | 14 shares |
About Corona Remedies IPO
Corona Remedies Limited is an India-focused branded pharmaceutical company specializing in developing and marketing products across high-growth chronic therapeutic areas, primarily women’s healthcare, cardio-diabeto, pain management, and urology. The company is recognized as the second-fastest-growing among the top 30 firms in the Indian Pharmaceutical Market (IPM) by domestic sales. It operates two manufacturing facilities in Gujarat and Himachal Pradesh and leverages a pan-India marketing network of 2,671 medical representatives.
Understanding Subscription Categories
QIB - Qualified Institutional Buyers
Includes foreign institutional investors, domestic financial institutions, mutual funds, and other qualified institutions. QIB demand is considered the most reliable indicator of institutional confidence in an IPO.
NII - Non-Institutional Investors
High net worth individuals applying above Rs 2 lakh. Divided into bNII (above Rs 10 lakh) and sNII (Rs 2 lakh to Rs 10 lakh). NII allotment is proportional.
Retail - Retail Individual Investors
Investors applying up to Rs 2 lakh per PAN. Allotment is by lottery when oversubscribed. Minimum one lot per successful applicant.
Corona Remedies IPO Subscription FAQs
What is Corona Remedies IPO IPO subscription status today?
Corona Remedies IPO IPO subscription closed on 10 December 2025 with overall subscription of 144.49x (by shares) as of 27 June 2026, 2:47 AM IST. QIB 293.80x, NII 86.61x, Retail 24.81x.
What is the overall subscription of Corona Remedies IPO IPO?
Corona Remedies IPO IPO is subscribed 144.49x overall by shares at close on 10 December 2025. QIB 293.80x, NII 86.61x, and Retail 24.81x.
What is Corona Remedies IPO IPO QIB subscription?
Corona Remedies IPO IPO QIB (Qualified Institutional Buyers) subscription is 293.80x by shares. QIB includes mutual funds, FIIs, banks, and other institutions.
What is Corona Remedies IPO IPO Retail subscription?
Corona Remedies IPO IPO Retail subscription is 24.81x by applications. Minimum retail bid is up to Rs 2 lakh per PAN.
What is Corona Remedies IPO IPO NII subscription?
Corona Remedies IPO IPO NII (Non-Institutional Investors) subscription is 86.61x by applications. NII covers bids above Rs 2 lakh.
What are allotment chances in Corona Remedies IPO IPO for retail?
At 24.81x subscription by applications, approximately 1 in 25 retail applicants can expect an allotment (~4% per application). Allotment is done by lottery. Share subscription was 30.29x. Allotment uses application count, not share volume.
When is Corona Remedies IPO IPO allotment date?
Corona Remedies IPO IPO allotment date is 11 December 2025. Check Corona Remedies IPO Allotment Status on IPOwiz from that day using your PAN.
When does Corona Remedies IPO IPO subscription close?
Corona Remedies IPO IPO subscription closed on 10 December 2025. No new applications are accepted after the close.
What is Corona Remedies IPO IPO GMP today?
Corona Remedies IPO IPO GMP is ₹342 today (+32.20% over issue price ₹1,062). See live GMP on the Corona Remedies IPO GMP Today page.
What is Corona Remedies IPO IPO issue price and lot size?
Corona Remedies IPO IPO issue price is ₹1,062 per share. Lot size is 14 shares. Minimum investment is ₹14,868 per lot. Issue size: ₹655.37 Cr.
When is Corona Remedies IPO IPO listing date?
Corona Remedies IPO IPO listing date is 15 December 2025 on NSE and BSE. Allotment is on 11 December 2025.
How does subscription affect Corona Remedies IPO IPO allotment?
Allotment odds in Corona Remedies IPO IPO depend on application subscription in each category, not share volume. Retail uses lottery when oversubscribed. NII proportional allotment at 86.61x by applications means roughly 1 in 87 for minimum-lot bids; bNII at 49.76x (~1 in 50). At 144.49x overall, competition is very high.
For allotment results from 11 December 2025, visit the Corona Remedies IPO Allotment Status page. For listing day updates on 15 December 2025, download the IPOwiz App.
Reviewed by Dinesh Agrawal
15+ years in Indian capital markets and IPO research. Subscription data verified before publish.